# BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT

> **NCT03229616** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 122 (estimated)

## Conditions studied

- Autologous Hematopoietic Stem Cell Transplantation
- Diffuse Large B-cell Lymphoma
- Conditioning

## Interventions

- **DRUG:** Busulfan (BU)
- **DRUG:** Cyclophosphamide (CY)
- **DRUG:** Etoposide (VP-16)

## Key facts

- **NCT ID:** NCT03229616
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-05
- **Primary completion:** 2020-06
- **Final completion:** 2020-06
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2017-10-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03229616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03229616, "BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03229616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*